Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Harvard School of Public Health Botswana Ministry of Health |
---|---|
Information provided by: | Harvard School of Public Health |
ClinicalTrials.gov Identifier: | NCT00197652 |
The goals of this study are to:
Condition | Intervention |
---|---|
HIV Infections |
Drug: Nevirapine Drug: Zidovudine |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Double-Blind, Placebo Control, Factorial Assignment |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Female |
Inclusion Criteria:
For HIV-infected subjects:
Exclusion Criteria:
Contact: Roger Shapiro, MD | 617-432-1023 | rshapiro@hsph.harvard.edu |
Botswana | |
Princess Marina Hospital | Recruiting |
Gaborone, Botswana | |
Contact: Ibou Thior, MD 723 02 632 |
Principal Investigator: | Roger Shapiro, MD | Harvard School of Public Health |
Study ID Numbers: | K23 HD001330-05 |
Study First Received: | September 12, 2005 |
Last Updated: | October 22, 2007 |
ClinicalTrials.gov Identifier: | NCT00197652 |
Health Authority: | United States: Institutional Review Board |
Prevention of Mother-Infant HIV Transmission |
Virus Diseases Nevirapine Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Zidovudine Retroviridae Infections Immunologic Deficiency Syndromes |
Antimetabolites Anti-Infective Agents RNA Virus Infections Anti-HIV Agents Slow Virus Diseases Immune System Diseases Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors |
Infection Antiviral Agents Pharmacologic Actions Reverse Transcriptase Inhibitors Anti-Retroviral Agents Therapeutic Uses Lentivirus Infections Nucleic Acid Synthesis Inhibitors |